Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Pharmacogenomics. 2011 Mar;12(3):327–339. doi: 10.2217/pgs.10.191

Figure 3. Association of principal component of expression of 60 validated probe sets with multiple phenotypes from the AML97 discovery set and AML02 validation set.

Figure 3

In the discovery set (AML97 cohort), the PC1 shows positive association with: (A) Ara-CTP levels; (B) improved morphological response; and (C) EFS. Within the validation set (AML02 cohort), PC1 shows: (D) negative association with LC50; (E) MRD; and (F) positive association with EFS.

Ara-CTP: Cytarabine 5´-triphosphate; CR: Complete response; EFS: Event-free survival; MRD: Minimal residual disease; NR: No response; PC1: First principal component; PR: Partial response.